Kornimate/medical-research-clean huggingface dataset:
exploring biomarkers for therapeutic response of lupus nephritis based on multi omics analysis

Conditions: Lupus Nephritis

Summary: this is an observational study of patients with lupus nephritis aiming to find biomarkers that can predict patients' response to immunosuppressants. we planed to collect 100 lupus nephritis patients' peripheral blood,kidney tissues and urine before and after treatment (mycophenolate mofetil or cyclophosphamide, in combination with glucocorticoids). then multi omics analysis, including single cell rna-seq, atac-seq and cite-seq, will be performed to find new biomarkers for patients' response and prognosis.


Eligibility criteria:
inclusion criteria: 1. age between 16-60 years. 2. fulfilling the 2012 slicc classification for sle. 3. renal biopsy pathology was clearly classified as iii \\ iv \\ v+iii \\ v+iv within 6 months. 4. renal biopsy reveals active disease. 5. 24-hour urinary protein was tested twice within two weeks, both of which were greater than 1g. 6. the patients have never received glucocorticoid/immunosuppressants or received standard treatment for more than 1 month without change. the standard treatment should fulfill: a. prednisone 0-20mg/day, or equivalent other glucocorticoids; b. acceptable immunosuppressants, including tacrolimus ≤ 4mg/d, methotrexate ≤ 15mg/week, azathioprine ≤ 100mg/d and mmf ≤ 1g/d. 7. informed consent obtained. exclusion criteria: 1. other concomitant connective tissue diseases or autoimmune diseases. 2. neuropsychiatric lupus, alveolar hemorrhage, retinal lesions, pulmonary arterial hypertension, or other severe organ involvement. 3. pregnant or lactating women. 4. current infections that require antibiotic or antiviral treatment. 5. other kidney diseases. 6. platelet \< 50×10\^9/l. 7. alanine aminotransferase (alt) or aspartate aminotransferase (ast) that is greater than 1.5 times the upper limit of the normal value. 8. total bilirubin or blood lipid that is greater than 2 times the upper limit of the normal value. 9. other conditions that not suitable for inclusion in the study, assessed by the investigators.

Keywords: lupus nephritis
vitamin d levels following topical application of vitamin d ointment

Conditions: Vitamin D Deficiency

Summary: this is a pre-post open label trial to assess the change in vitamin d blood levels following treatment with three doses of topical vitamin d3 in subjects with existing vitamin d deficiency.

the proposed study investigates safety and efficacy of a new topical vitamin d3 compound. the purpose of this phase 1 trial is to determine whether topical application makes vitamin d bioavailable to the systemic circulation in sufficient quantities to treat hypovitaminosis d. the study will assess the change in serum 25-hydroxy (25-oh) vitamin d concentrations following 3 doses of 100,000 iu or 3 doses of 300,000 iu of topical vitamin d3 ointment in volunteers with vitamin d deficiency. adults with serum 25-oh vitamin d concentrations of \< 20 ng/ml will receive a total of 300,000 iu or 900,000 iu in divided doses of topical vitamin d once per week for three weeks. two 0.75 ml applicators of ointment will be applied to each upper arm (50,000 iu or 150,000 iu per arm) by study staff. blood will be drawn at baseline prior to the first dose (day 0) and on days 7, 14, and 21. total serum 25-oh vitamin d will be assayed at each draw. parathyroid hormone, a measure of clinical effects of low vitamin d levels, will be checked at baseline and on day 21. serum albumin adjusted calcium levels will be checked with each draw to check for possible effects of too much vitamin d absorption. the study will determine whether the topical application of vitamin d ointment is able to correct existing vitamin d deficiency.

Eligibility criteria:
inclusion criteria: 1. known vitamin d deficiency based on blood work obtained prior to study consent defined as serum 25-hydroxyvitamin d less than or equal to 20 ng/ml within 30 days prior to study entry. 2. adult, age 18 to 85 years, male or female 3. if on oral vitamin d therapy, have been on a stable dose for the previous 90 days. exclusion criteria: 1. history of chronic liver disease with elevated liver function tests, chronic kidney disease (stage 3 or greater, egfr \<60 ml/min), uncontrolled thyroid disease (elevated thyroid function tests), primary or secondary hyperparathyroidism, hypercalcemia, or multiple endocrine neoplasia. 2. hypercalcemia defined as either elevated corrected serum calcium \>10.2 mg/dl) measured within 3 months prior to study. 3. estimated glomerular filtration rate (egfr) \<60 ml/min within 3 months prior to study. 4. active cancers 5. women who are pregnant or breastfeeding. 6. individuals who are unable to give informed consent 7. individuals with psoriasis, active eczema or other skin disease, or who are currently receiving treatments or medications for skin disease. 8. individuals who do not agree to refrain from using tanning beds for the duration of the study. 9. individuals who do not agree to avoid submerging the ointment site in water for 8 hours after ointment application.
epidemiological study of the prevalence of age-related macular degeneration in portugal

Conditions: Age-Related Macular Degeneration

Summary: this is an epidemiological study to assess the the prevalence of age-related macular (arm) degeneration in portugal.


Eligibility criteria:
inclusion criteria: * participants with 55 years-old exclusion criteria: * none
medico-economic evaluation of a project of wounds by a remote network

Conditions: Resident of Languedoc-roussillon; Carrying a Chronic Wound

Summary: estimate in 6 months the impact of the telemedicine on the cure rate of the chronic wounds compared with the usual care(with or without cicat-lr network).


Eligibility criteria:
inclusion criteria: * being adult * taken up residence on the languedoc-roussillon * patient carrying a wound with healing or improvement objective (wound closure or the appearance of 40% of granulation) * informed consent signed, * patient member of the security social * patient having a visiting nurse. exclusion criteria: * patient in vital or functional emergency situation during the first call or during the consultation * tumoral wound * dialysis patient * arteritis of stage 4 and not revascularizable * absence of regular doctor and visiting nurse * patient refusal * refusal of one of the health professionals participating in the pathology care * anybody incapable to communicate and to answer the questions * pregnant or nursing woman * subject deprived of freedom by court or administrative order * major subject protected by the law * for the patients in telemedicine: refusal of the collaboration agreement

Keywords: chronic wound tablet telemedicine wounds consultation smartphone
phna, efficacy of tretinoin cream on post-phototherapy hyperpigmentation

Conditions: Vitiligo

Summary: a randomized controlled split-face pilot study was planned to investigate the preventive effect of tretinoin 0.05% cream on hyperpigmentation during phototherapy in patients with vitiligo.

vitiligo is a chronic depigmentation disorder characterized by well-demarcated white macules and patches, reflecting selective melanocyte destruction. hyperpigmentation at the treated areas is one of the limitations of phototherapy. topical tretinoin (retinoic acid) has been well established to be effective for skin pigmentary disorders including melasma. this study aims to investigate the preventive effect of topical tretinoin on hyperpigmentation during phototherapy. a randomized controlled trial based on split-face was planned. the left/right face will be randomized to either tretinoin or placebo cream treatment groups. all lesions will be treated using phototherapy twice weekly for a total of 12-week period. the degree of repigmentation will be assessed as % from baseline by using a computer program every 4 weeks.

Eligibility criteria:
inclusion criteria: * age: older than 19 * a patient with stable non-segmental vitiligo * a patient with symmetrical vitiligo lesions on face * a patient with the willingness to comply with the study protocol during the study period and capable of complying with it. * a patient who signed the informed consent prior to the participation of the study and who understands that he/she has a right to withdrawal from participation in the study at any time without any disadvantages. exclusion criteria: * age: lower than 20 * a pregnant or lactating patient * a patient with active or spreading vitiligo * a patient who cannot understand the study or who does not sign the informed consent * women of childbearing potential not using an effective method of contraception properly
cerebellum - cognitive outcome and functional connectivity

Conditions: Childhood Cerebellar Tumor

Summary: aim: to investigate the effect of cerebellar tumor surgery on the resting state functional connectivity level in higher order cognition networks known to interact with the cerebellum. furthermore, to correlate the connectivity level of these networks with the neuropsychological performance and functional outcome of the patients. the investigator's hypothesis is that the functional connectivity of various cognition networks in the cerebrum as assessed by resting-state functional magnetic resonance imaging can be impaired after cerebellar tumor surgery and can be correlated with the neuropsychological performance. the effect of surgery on the cognition networks and the neuropsychological performance is dependent on the tumor location within the cerebellum. such a correlation seems feasible as functional connectivity analysis could be correlated with the neuropsychological impairment in various neuropsychiatric disorders. furthermore, investigators were able to depict the maturation of the functional connectivity networks in parallel to the neurocognitive development in childhood


Eligibility criteria:
inclusion criteria: * • male or female patients aged \> 15 yrs * age at surgery between 1 yrs - 12 yrs * compliance (the patients have to be able to lay motionless in a 3 tesla mr scanner and to cooperate with the examiner during the examination) * signed informed consent from the patient and/or the parents exclusion criteria: * • patients with neurofibromatosis 1 * severe visual or auditory impairment * cerebrospinal fluid shunt device * prior radiotherapy or chemotherapy * contraindications to mri
kinesiophobia, pain, balance, quality of life and mental status in hemodialysis patients

Conditions: Hemodialysis; End Stage Renal Disease (ESRD)

Summary: the aim of our study was to investigate the relationship between kinesiophobia and pain, balance, physical performance, quality of life and mental status in patients receiving hemodialysis.


Eligibility criteria:
inclusion criteria: * patients with end stage renal disease receiving hemodialysis * receiving hemodialysis for more than 3 months * being clinically stable * volunteering to participate in this stud exclusion criteria: -having musculoskeletal disorders that may affect physical performance
hypofractionated pbi after bcs for low-risk breast cancer patients

Conditions: Breast Cancer

Summary: the study was designed to evaluate the feasibility and safety of hypofractionated partial breast irradiation after breast-conserving surgery for low-risk breast cancer patients.

a total dose of 40.05gy in 15 fractions was delivered to the tumor bed for each eligible breast cancer patients. the endpoints including loco-regional recurrence, cosmetic outcomes, and toxicities, were evaluated after treatment.

Eligibility criteria:
inclusion criteria: * female * age≥ 50 years * treated with breast conversing surgery and sentinel lymph node biopsy or axillary lymph node dissection * negative surgical margins * pathologically confirmed invasive breast cancer * a pathological t1n0m0 tumor -ihc: er+/pr+/her2- * tumor bed is labeled with titanium clips * received adjuvant hormonal treatment * no adjuvant chemotherapy * ecog:0-1 * written informed consent. exclusion criteria: * age\<50 years * kps\<70 * treated with neoadjuvant chemotherapy * treated or being treated with chemotherapy * with severe comorbidity * previous breast cancer or other malignant tumor history * previous radiotherapy for breast or thorax * medical contraindication for radiotherapy * pregnant or nursing

Keywords: breast cancer hypofractionated partial breast irradiation
high-dose, short-term steroid and low-dose long-term steroid use in ards caused by covid-19

Conditions: Short-term (3 Days) High-dose (1000 mg) Systemic Methylprednisolone

Summary: in this study, we aimed to compare, retrospectively, the 15-day continuous hemodynamic, laboratory and clinical course of covid 19 patients to whom we administered short-term (3 days) high-dose (1000 mg) systemic methylprednisolone with those to whom low-dose long-term (2x 40 mg) systemic methylprednisolone was administered.


Eligibility criteria:
inclusion criteria: * between june 1, 2020 and february 1, 2021, hospitalized in the general intensive care unit of biruni university medical faculty hospital with the diagnosis of covid 19; * patients over 18 years of age; (for the diagnosis of covid 19; identification of sars-cov-2 by reverse transcription-polymerase chain reaction (rt-pcr) in nasopharyngeal swab or sputum samples and abnormal lung computed tomography finding (ct) scan finding with \<90% oxygen saturation at rest (bilateral, subpleural, peripheral ground glass opacities) exclusion criteria: * patients with a diagnosis of steroid allergy or developing during treatment; * pregnant or lactating women; * patients with active malignancy; * patients taking any immunosuppressive agent.
to assess the level of adherence of subjects receiving saizen® via easypod™ in greece

Conditions: Growth Disorders

Summary: this is a national, multicentre, observational registry to study adherence and long term outcomes of therapy in paediatric subjects using easypod™ electromechanical device for growth hormone treatment from hospitals in greece and to assess the level of adherence of subjects receiving saizen® via easypod™.

subjects will be enrolled in a multicenter, longitudinal observational registry. parents/subjects will provide their informed consent/assent to upload their data for populationbased analyses and optionally to adhere to a patient adherence support program designed to improve their adherence and, ultimately, clinical outcomes. adherence data will be primarily derived from the easypod™ device combined with physician data entry of outcome measures. data will be collected retrospectively and prospectively. this will allow the establishment of adherence profiles and explore the hypothesis that patient adherence support programs improve adherence and subsequent clinical outcomes. collected data will be also analyzed in a multinational pooled analysis of comparable national studies. primary objective: - to assess the level of adherence of subjects receiving saizen® via easypod™ secondary objectives: * to identify adherence subject profiling * to describe the impact of adherence on clinical outcomes for subject receiving saizen® via easypod™ * to asses the impact of adherence on insulin-like growth factor 1 (igf1) (i.e. above, below or within normal ranges) * to assess/describe the impact of the greek scientific service (patient support program)

Eligibility criteria:
inclusion criteria: * administered growth hormone (saizen®) via the easypod™ auto-injector, according to approved summary of product characteristics (smpc) * naïve subjects or already treated with saizen® and easypod™ for up to 1 year * male and female between 2 - 18 years of age, or over 18 without fusion of growth plates * parent's or guardian's (or subject's if over 18 without fusion of growth plates) written informed consent, given before entering data into the registry, with the understanding that the subject or parent/guardian may withdraw consent at any time without prejudice to future medical care. exclusion criteria: * subjects taking growth hormone in whom growth plates have fused (i.e. for taking growth hormone for its metabolic effects) * contra-indications to saizen® as defined in the approved smpc * use of an investigational drug or participation in another interventional clinical study

Keywords: growth disorders saizen easypod growth hormone pediatric subject
air suspension biodegradable patient transport pad

Conditions: Critical Illness

Summary: on the one hand, transferring patient from bed to bed is usually handling by the manual lifting of several staffs or utilizing bedsheet, slide sheet , shovel-style stretcher or other devices to move and lift patients. whatever, there are some advantages using these devices. on the other hand, nurses are among the professionals at the highest risk for musculoskeletal disorders. the bureau of labor statistics has shown that overexertion in manual lifting was the main event or exposure leading to injury or illness involving time away from work. excessive weights, awkward postures, and repetitive motions are some of the known risk factors that contribute to sprains/strains and back injuries. during the process of patient transferring , it refers to the above risk factors for health-care workers. it recommended that using appropriate assistive equipment can reduce the injuries. if staff is safe, patients are safer. the research team has designed and produced a new transport assistive devices-- biodegradable and air-suspending transfer mattress, which was precisely controlled by gas flow and based on ergonomics. and then apply it to the clinic in order to find whether it's benefit for patients and nursing staff. it is a randomized controlled trial design.

research design：randomized controlled trials. computer generated random numbers. the patients were randomly divided into three groups, ① transfer patients by air-suspending mattress, ② transfer patients by slide board, ③ transfer patients by bedsheets. participants: passive patient with transports needs, such as ct/ mri examination etc. the sample size estimation was according to the formula of multiple parallel design. the main outcome measure was the perceived exertion.

Eligibility criteria:
inclusion criteria: * passive patient with transfer requirements, such as ct/ mri examination , transfer from one department to another etc；patients or their family signed an informed consent. exclusion criteria: * the patients weighted over 150kg and have spine fracture ；age\< 15 years old.
military women's health and illness behaviors in deployed settings

Conditions: Genitourinary Symptoms

Summary: the purpose of this study is to gain better understanding of how recently deployed military women managed urinary and vaginal symptoms while deployed. participants in this study will be asked to take part in a 45-60 minute interview.


Eligibility criteria:
inclusion criteria: * deployment within the last 12 months * managed genitourinary symptoms while deployed (does not have to be diagnosed by a medical provider) exclusion criteria: * women who are assigned to a medical group/hospital

Keywords: military women women's health genitourinary symptoms illness behaviors to determine how women manage genitourinary symptoms while deployed.
sex differences, hormones & smoking cessation

Conditions: Tobacco Cessation

Summary: data suggest that progesterone may improve smoking cessation outcomes perhaps by reducing impulsive behavior. however, the clinical literature on this topic is lacking. therefore, in project i we are proposing a double-blind randomized controlled trial to assess the role of exogenous progesterone on impulsivity and smoking cessation in a sample of males and females who are motivated to quit smoking.

subjects will be stratified by sex and then randomly assigned to active progesterone (pro) or placebo (pbo). telephone screening and visit invitation leads to the consent process and in-person screening including medical-psychiatric evaluation for inclusion/exclusion, then randomization and medication induction, stable medication with medication reduction and final evaluation for secondary outcomes.

Eligibility criteria:
inclusion criteria: * male 18 to 60 years old * female 18 to 50 years old * self-report regular smoking * motivated to quit smoking * in stable physical/mental health * self report of regular menstrual cycles (female only) * english fluency * understand the study procedures and able to provide informed consent * ability to participate fully in research elements for the duration of the trial. exclusion criteria: * current or recent (\< 3 months) breastfeeding (females only) * current or planned pregnancy within the next three months (females only) * conditions contraindicated to progesterone treatment.
text messaging to improve adherence to repeat colonoscopy in a veterans affairs (va) hospital

Conditions: Colorectal Cancer

Summary: colorectal cancer is a common but preventable condition, and increasing colorectal cancer screening is one of the most impactful public health contributions in the field of gastroenterology. text messaging is a simple, cheap, and rapid method to reach patients that may improve adherence to colonoscopy appointments as well as simplify the process of bowel preparation. the purpose of the study is to evaluate the feasibility of a pilot bidirectional text messaging intervention on attendance for screening/surveillance colonoscopy and bowel preparation quality at an urban va hospital. the goal is to improve adherence to colonoscopy among patients who are due for a repeat colonoscopy.


Eligibility criteria:
inclusion criteria: • has previously undergone a colonoscopy and is currently due for a repeat screening or surveillance colonoscopy at the va. exclusion criteria: * patients not due for screening or surveillance colonoscopy. this will be based on 2020 guidelines from the u.s. multi-society task force on colorectal cancer. * patients with personal history of colorectal cancer (crc)/inflammatory bowel disease/ hereditary colon cancer syndrome or family history of hereditary colon cancer syndrome. these criteria will be determined based on icd9/10 codes or the medical record.
understanding performance: enhancing recovery as surgeons

Conditions: Burnout, Professional

Summary: reliably achieving peak performance requires balancing the strain of the prior day with sufficient recovery to be ready for the next day. surgery has a long standing tradition long hours of hard work often at the expense of adequate sleep. decreased sleep and recovery has physiologic consequences which can be measured using biometric data. the goal of this study is to quantify surgeon performance and biometric data to understand how modifiable behaviors can maximize recovery and performance.

participants will be asked to wear a biometric sensor for six months. the biometric sensor, namely, 'the whoop strap' collects heart rate and heart rate variability data. other data gathered will be in the form of surveys and comments from subjects on wellness, burnout, modifiable activities including sleep, nutrition, exercise and mindfulness, and surgical performance as well as video and audio recordings during a simulated surgical task. surveys will be individually numbered and a master list of subject number and video, audio, and sensor id will be kept in a separate location. this practice will enable us to better understand survey feedback by reviewing relevant videos, images, and sensor recordings. images and data associated with a subject will be labeled with the subject number only.

Eligibility criteria:
inclusion criteria: * study participants will include trainee and attending surgeons exclusion criteria: * exclusion criteria will be anyone who is not full-time clinically active as a surgical trainee or attending